MiNK Therapeutics (INKT) announced that new translational data supporting the role of invariant natural killer T cells in idiopathic pulmonary fibrosis were presented at the Emerging Cell Therapies Meeting of the Keystone Symposia on Molecular and Cellular Biology, taking place February 1-4, in Banff, Alberta, Canada. The data demonstrate a significant depletion of invariant natural killer T cells in lung-associated lymph nodes from patients with end-stage idiopathic pulmonary fibrosis, supporting a mechanistic role for iNKT insufficiency in advanced disease.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT: